Darbepoetin alfa
-
Subject Areas on Research
- American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
- American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
- Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
- Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.
- Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
- Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
- Erythropoiesis-stimulating protein support and survival.
- Erythropoietin: high profile, high scrutiny.
- Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
- Myelodysplastic syndromes.
- Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
- Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
- Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
- Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
- The ASCEND-ND trial: study design and participant characteristics.
- The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma.
- Treatment of anemia with darbepoetin alfa in systolic heart failure.
- Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
- Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.